Pelvic autonomic dysfunction is common in patients with pure autonomic failure.
bowel dysfunction
lower urinary tract dysfunction
nocturnal polyuria
pelvic autonomic dysfunction
pure autonomic failure
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
revised:
23
08
2024
received:
24
03
2024
accepted:
29
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
30
9
2024
Statut:
aheadofprint
Résumé
Pure autonomic failure (PAF) presents primarily as cardiovascular autonomic failure and may phenoconvert to other neurodegenerative disorders. However, the involvement of other autonomic functions has been poorly evaluated. This study aims to characterize genitourinary and bowel dysfunction and explore their relationship with cardiovascular autonomic dysfunction. Pure autonomic failure patients underwent cardiovascular autonomic testing and an assessment of pelvic autonomic dysfunction using urinary, sexual symptoms questionnaires and a bladder diary. Demographic, clinical features and related medical comorbidities were assessed. Twenty-five patients (10 males) with PAF were included (mean age 71 ± 8 years; disease duration 13 ± 8 years). 96% (24/25) reported lower urinary tract symptoms, of which overactive bladder symptoms were most commonly reported (n = 23; 92%; median overactive subscore 8, interquartile range [IQR] 3-11), followed by voiding difficulties (n = 19; 76%; median low stream subscore 2, IQR 1-3) using the Urinary Symptom Profile; however, only four (16%) required clean intermittent self-catheterization. Sexual dysfunction was common (n = 21; 84%) using the Arizona Sexual Experience Scale. Mild faecal incontinence and constipation were reported. 86% (19/22) had nocturnal polyuria (NP) and the median NP index was 47% (IQR 38%-51%; normal range <33%). 77% (10/13) had voiding dysfunction and 31% (4/13) had post-void residual urine >100 mL. There were no significant correlations between the need for catheterization and the degree of NP with age, disease duration and cardiovascular autonomic parameters (p > 0.05). Nocturnal polyuria, genitourinary and bowel symptoms are commonly seen in PAF. The pathophysiology of NP in PAF is most likely multifactorial and may occur independent of cardiovascular autonomic failure.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Pure autonomic failure (PAF) presents primarily as cardiovascular autonomic failure and may phenoconvert to other neurodegenerative disorders. However, the involvement of other autonomic functions has been poorly evaluated. This study aims to characterize genitourinary and bowel dysfunction and explore their relationship with cardiovascular autonomic dysfunction.
METHODS
METHODS
Pure autonomic failure patients underwent cardiovascular autonomic testing and an assessment of pelvic autonomic dysfunction using urinary, sexual symptoms questionnaires and a bladder diary. Demographic, clinical features and related medical comorbidities were assessed.
RESULTS
RESULTS
Twenty-five patients (10 males) with PAF were included (mean age 71 ± 8 years; disease duration 13 ± 8 years). 96% (24/25) reported lower urinary tract symptoms, of which overactive bladder symptoms were most commonly reported (n = 23; 92%; median overactive subscore 8, interquartile range [IQR] 3-11), followed by voiding difficulties (n = 19; 76%; median low stream subscore 2, IQR 1-3) using the Urinary Symptom Profile; however, only four (16%) required clean intermittent self-catheterization. Sexual dysfunction was common (n = 21; 84%) using the Arizona Sexual Experience Scale. Mild faecal incontinence and constipation were reported. 86% (19/22) had nocturnal polyuria (NP) and the median NP index was 47% (IQR 38%-51%; normal range <33%). 77% (10/13) had voiding dysfunction and 31% (4/13) had post-void residual urine >100 mL. There were no significant correlations between the need for catheterization and the degree of NP with age, disease duration and cardiovascular autonomic parameters (p > 0.05).
CONCLUSIONS
CONCLUSIONS
Nocturnal polyuria, genitourinary and bowel symptoms are commonly seen in PAF. The pathophysiology of NP in PAF is most likely multifactorial and may occur independent of cardiovascular autonomic failure.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16486Informations de copyright
© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology. 1996;46(5):1470.
Mathias CJ, Mallipeddi R, Bleasdale‐Barr K. Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy. J Neurol. 1999;246(10):893‐898.
Kaufmann H, Norcliffe‐Kaufmann L, Palma JA, et al. Natural history of pure autonomic failure: a United States prospective cohort. Ann Neurol. 2017;81(2):287‐297.
Herschorn S, Staskin D, Schermer CR, Kristy RM, Wagg A. Safety and tolerability results from the PILLAR study: a phase IV, double‐blind, randomized, placebo‐controlled study of Mirabegron in patients >/= 65 years with overactive bladder‐wet. Drugs Aging. 2020;37(9):665‐676.
Singer W, Berini SE, Sandroni P, et al. Pure autonomic failure: predictors of conversion to clinical CNS involvement. Neurology. 2017;88(12):1129‐1136.
Giannini G, Calandra‐Buonaura G, Asioli GM, et al. The natural history of idiopathic autonomic failure: the IAF‐BO cohort study. Neurology. 2018;91(13):e1245‐e1254.
Coon EA, Mandrekar JN, Berini SE, et al. Predicting phenoconversion in pure autonomic failure. Neurology. 2020;95(7):e889‐e897.
Yamanaka Y, Sakakibara R, Asahina M, et al. Chronic intestinal pseudo‐obstruction as the initial feature of pure autonomic failure. J Neurol Neurosurg Psychiatry. 2006;77(6):800.
Haab F, Richard F, Amarenco G, et al. Comprehensive evaluation of bladder and urethral dysfunction symptoms: development and psychometric validation of the urinary symptom profile (USP) questionnaire. Urology. 2008;71(4):646‐656.
Bonniaud V, Bryant D, Parratte B, Guyatt G. Development and validation of the short form of a urinary quality of life questionnaire: SF‐Qualiveen. J Urol. 2008;180(6):2592‐2598.
McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25‐40.
Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993;36(1):77‐97.
Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum. 1996;39(6):681‐685.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub‐committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167‐178.
Mathias CJ, Bannister R. Autonomic Failure: a Textbook of Clinical Disorders of the Autonomic Nervous System. 5th ed. Oxford University Press; 2013.
Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697‐716.
Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69‐72.
Hague K, Lento P, Morgello S, Caro S, Kaufmann H. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol. 1997;94(2):192‐196.
Shishido T, Ikemura M, Obi T, et al. Alpha‐synuclein accumulation in skin nerve fibers revealed by skin biopsy in pure autonomic failure. Neurology. 2010;74(7):608‐610.
Sakakibara R, Hattori T, Uchiyama T, Asahina M, Yamanishi T. Micturitional disturbance in pure autonomic failure. Neurology. 2000;54(2):499‐501.
Vichayanrat E, Hentzen C, Batla A, Simeoni S, Iodice V, Panicker JN. Lower urinary tract dysfunction in parkinsonian syndromes. Neurol Sci. 2021;42(10):4045‐4054.
Bosch JL, Everaert K, Weiss JP, et al. Would a new definition and classification of nocturia and nocturnal polyuria improve our management of patients? ICI‐RS 2014. Neurourol Urodyn. 2016;35(2):283‐287.
Smith M, Seth J, Batla A, Hofereiter J, Bhatia KP, Panicker JN. Nocturia in patients with Parkinson's disease. Mov Disord Clin Pract. 2016;3(2):168‐172.
Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire‐based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci. 2001;92(1–2):76‐85.
Chaudhuri KR, Martinez‐Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord. 2006;21(7):916‐923.
Stewart RB, Moore MT, May FE, Marks RG, Hale WE. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc. 1992;40(12):1217‐1220.
Temml C, Ponholzer A, Gutjahr G, Berger I, Marszalek M, Madersbacher S. Nocturia is an age‐independent risk factor for hip‐fractures in men. Neurourol Urodyn. 2009;28(8):949‐952.
Nakagawa H, Niu K, Hozawa A, et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol. 2010;184(4):1413‐1418.
Parsons JK, Mougey J, Lambert L, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int. 2009;104(1):63‐68.
Pesonen JS, Cartwright R, Vernooij RWM, et al. The impact of nocturia on mortality: a systematic review and meta‐analysis. J Urol. 2020;203(3):486‐495.
Romain J, Torny F, Dumas JP, Game X, Descazeaud A. Is nocturnal polyuria more frequent among patients with Parkinson's disease? Prog Urol. 2015;25(6):312‐317.
Sakakibara R, Shimizu A, Takahashi O, et al. Parkinson's disease and nocturnal polyuria. Neurol Clin Neurosci. 2023;11(1):27‐31.
Asplund R. Diuresis pattern, plasma vasopressin and blood pressure in healthy elderly persons with nocturia and nocturnal polyuria. Neth J Med. 2002;60(7):276‐280.
Weiss JP, Monaghan TF, Epstein MR, Lazar JM. Future considerations in nocturia and nocturnal polyuria. Urology. 2019;133S:34‐42.
Birder LA, Van Kerrebroeck PEV. Pathophysiological mechanisms of nocturia and nocturnal polyuria: the contribution of cellular function, the urinary bladder urothelium, and circadian rhythm. Urology. 2019;133S:14‐23.
Sakakibara R, Panicker J, Finazzi‐Agro E, Iacovelli V, Bruschini H. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551‐563.
Matthiesen TB, Rittig S, Norgaard JP, Pedersen EB, Djurhuus JC. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol. 1996;156(4):1292‐1299.
Garland EM, Gamboa A, Okamoto L, et al. Renal impairment of pure autonomic failure. Hypertension. 2009;54(5):1057‐1061.
Tikkinen KA, Johnson TM 2nd, Tammela TL, et al. Nocturia frequency, bother, and quality of life: how often is too often? A population‐based study in Finland. Eur Urol. 2010;57(3):488‐496.
Wilmanski T, Rappaport N, Earls JC, et al. Blood metabolome predicts gut microbiome alpha‐diversity in humans. Nat Biotechnol. 2019;37(10):1217‐1228.
Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104(3):352‐360.
van Doorn B, Blanker MH, Kok ET, Westers P, Bosch JL. Prevalence, incidence, and resolution of nocturnal polyuria in a longitudinal community‐based study in older men: the Krimpen study. Eur Urol. 2013;63(3):542‐547.
Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord. 1995;10(3):337‐340.